04:39 AM EST, 11/26/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) said Tuesday it has agreed to be acquired by Roche Holdings in a deal that has an equity value of about $1.5 billion on a fully diluted basis.

Roche will launch a tender offer to acquire all of Poseida's outstanding shares for $9 per share in cash plus a non-tradeable contingent value right to receive up to $4 per share in cash at the achievement of certain milestones.

The transaction is expected to close in Q1 2025, subject to conditions including the tender of shares representing at least a majority of Poseida's outstanding shares, the company said.

Poseida and its employees will join Roche as part of its pharmaceuticals division, the company said.

Shares of Poseida Therapeutics ( PSTX ) jumped more than 200% in premarket activity Tuesday.